regardless of encouraging clinical results, copyright's Vyndamax, a therapy for hereditary transthyretin-mediated amyloidosis (hATTR), is facing substantial resistance from pharmacy benefit managers. Such organizations are frequently building barriers to reimbursement, such as steep cost requirem